.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03C_Estrogens.G03CA09_Promestriene.Promestriene .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03C_Estrogens.G03CA09_Promestriene.Promestriene| name: | Promestriene | |
| ATC code: | G03CA09 | route: | vaginal |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Promestriene is a synthetic derivative of estradiol (an estrogen), primarily used as a topical treatment in gynecology for symptoms of vaginal atrophy, such as dryness, irritation, and itching. It is not considered a systemic estrogen and is mostly used in local therapy (e.g., vaginal creams or ovules). As of 2024, pro-mestriene is not approved for use in the United States but has been available in some European, Latin American, and Asian markets.
No peer-reviewed publications with specific pharmacokinetic parameters of pro-mestriene in humans were found. Due to its almost exclusively topical (vaginal) administration and negligible systemic absorption, systemic pharmacokinetic parameters are generally unreported and are likely clinically irrelevant.